7-[(3S)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1)

Description:
The compound is a pharmaceutical drug that belongs to the class of amination. It contains nitrogen atoms, which are enantioselectively substituted with amino groups. There are two strategies for the introduction of an amino group on a nitrogen atom: (i) addition of an amine to the nitrogen atom and (ii) substitution of a hydrogen atom on the nitrogen atom with an electron-withdrawing group. The amines used in this process are usually motivated by functionalized electrophiles or allylic functionalities. In order to make this compound, a multistep process was necessary, involving nonactivated electrophiles such as halides, sulfonates, or nitro groups. This is because the introduction of an amino group can be achieved using either a chiral or racemic catalyst system.